

SARS-CoV-2-associated ssRNAs activate inflammation and immunity via TLR7/8


Valentina Salvi, ... , Silvano Sozzani, Daniela Bosisio

JCI Insight. 2021;6(18):e150542. <https://doi.org/10.1172/jci.insight.150542>.

Research Article

Immunology

Graphical abstract



Find the latest version:

<https://jci.me/150542/pdf>



SARS-CoV-2-associated ssRNAs activate inflammation and immunity via TLR7/8

Valentina Salvi,¹ Hoang Oanh Nguyen,¹ Francesca Sozio,^{1,2} Tiziana Schioppa,^{1,2} Carolina Gaudenzi,¹ Mattia Laffranchi,¹ Patrizia Scapini,³ Mauro Passari,¹ Ilaria Barbazza,¹ Laura Tiberio,¹ Nicola Tamassia,³ Cecilia Garlanda,^{2,4} Annalisa Del Prete,^{1,2} Marco A. Cassatella,³ Alberto Mantovani,^{2,4,5} Silvano Sozzani,^{6,7} and Daniela Bosisio¹

¹Department of Molecular and Translational Medicine, University of Brescia, Italy. ²IRCCS Humanitas Research Hospital, Rozzano (MI), Italy. ³Department of Medicine, Section of General Pathology, University of Verona, Italy. ⁴Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy. ⁵The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom. ⁶Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy. ⁷IRCCS Neuromed, Pozzilli (IS), Italy.

The inflammatory and IFN pathways of innate immunity play a key role in the resistance and pathogenesis of coronavirus disease 2019 (COVID-19). Innate sensors and SARS-CoV-2-associated molecular patterns (SAMPs) remain to be completely defined. Here, we identified single-stranded RNA (ssRNA) fragments from the SARS-CoV-2 genome as direct activators of endosomal TLR7/8 and MyD88 pathway. The same sequences induced human DC activation in terms of phenotype and function, such as IFN and cytokine production and Th1 polarization. A bioinformatic scan of the viral genome identified several hundreds of fragments potentially activating TLR7/8, suggesting that products of virus endosomal processing potently activate the IFN and inflammatory responses downstream of these receptors. In vivo, SAMPs induced MyD88-dependent lung inflammation characterized by accumulation of proinflammatory and cytotoxic mediators and immune cell infiltration, as well as splenic DC phenotypical maturation. These results identified TLR7/8 as a crucial cellular sensor of ssRNAs encoded by SARS-CoV-2 involved in host resistance and the disease pathogenesis of COVID-19.

Introduction

SARS-CoV-2 is a positive-sense single-stranded RNA (ssRNA) virus belonging to the family of Coronaviridae, also including the closely related Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV (1). In a subgroup of patients, SARS-CoV-2 infection (coronavirus disease 2019, COVID-19) develops as acute respiratory distress syndrome featuring intense lung injury, sepsis-like manifestations, and multiorgan failure (2) associated with overt production of proinflammatory cytokines that directly correlates with poor prognosis (3). This clinical condition suggests that an overactive innate immune response may unleash virus-dependent immune pathology (4). Innate immune activation is also responsible for inducing the protective antiviral state, largely mediated by the release of type I IFNs. Indeed, inborn errors in type I IFN production and amplification (5) or preexisting blocking autoantibodies against members of the IFN family of cytokines (6) were found to correlate with unfavorable prognosis.

DCs act as crucial messengers linking innate and adaptive immunity against viral infections (7, 8). Within DC heterogeneity, plasmacytoid DCs (pDCs) play an important role as the major source of type I IFN in response to viral infection, while conventional DCs (cDCs) respond to a vast variety of pathogens by producing proinflammatory cytokines and are the main cells responsible for T cell activation (9–11). pDCs sense ssRNA viruses through TLR7 (12), an endosomal receptor activated by genomic fragments rich in guanine and uracil (GU rich), derived by endosomal processing of the virus independently of infection (13). By contrast, cDCs express the closely related TLR8 (14). Although TLR7 and TLR8 display high structural and functional homology and similar ligand specificity (15) and recruit the same signaling intracellular adaptor molecule, MyD88 (16), the signaling pathways of these 2 TLRs diverge in functional significance, with TLR7 more involved in the antiviral immune response and TLR8 mastering the production of proinflammatory cytokines. Both cDCs and pDCs were shown to be reduced in the blood of patients with severe acute COVID-19 (17, 18) as a possible

Conflict of interest: The authors have declared that no conflict of interest exists.

Copyright: © 2021, Salvi et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Submitted: April 14, 2021

Accepted: August 4, 2021

Published: September 22, 2021

Reference information: *JCI Insight*. 2021;6(18):e150542.

<https://doi.org/10.1172/jci.insight.150542>.

insight.150542.

result of cell activation (19), but the mechanisms of SARS-CoV-2 recognition and activation by innate immune cells still need to be identified. This study characterized SARS-CoV-2-associated molecular patterns (SAMPs) and identified the TLR7/8/MyD88 axis as a crucial pathway in the activation of human pDCs and cDCs.

Results

Identification of potential ssRNA SAMPs. Based on previous work identifying RNA40, a GU-rich ssRNA from the U5 region of HIV-1, as a natural agonist of TLR7 and TLR8 (20) and on known features of TLR7/8 ligands (15, 21, 22), we searched for putative immunostimulatory sequences within the SARS-CoV-2 ssRNA genome. Our bioinformatic scan revealed 491 GU-rich sequences, among which more than 250 also bore at least 1 “UGUGU” IFN induction motif (IIM; refs. 15, 20, 21; Supplemental Table 1; supplemental material available online with this article; <https://doi.org/10.1172/jci.insight.150542DS1>).

We hypothesized that these sequences may represent as yet unidentified SAMPs responsible for viral recognition and immune activation via endosomal TLR triggering. The elevated number of sequences detected suggests that upon endosomal engulfment, the fragmentation of the SARS-CoV-2 genome may generate many TLR7/8-triggering sequences, thus displaying a high chance of contacting and activating the IFN and inflammatory responses downstream of these receptors.

To validate the stimulatory potential on innate immune cells, 2 representative sequences, SCV2-RNA1 and SCV2-RNA2, were chosen within the previous list, synthesized, and tested in *in vitro* and *in vivo* models of inflammation.

ssRNA SAMPs activate human monocyte-derived DCs. Monocyte-derived DCs (moDCs), a model of inflammatory cDCs expressing a wide variety of TLRs (7, 23–25), were treated with increasing concentrations of SCV2-RNA1 and SCV2-RNA2 along with HIV-1–derived RNA40 (20) used as a positive control. Uridine/adenosine–alternated (U/A–alternated) control sequences SCV2-RNA1A and SCV2-RNA2A were used as negative controls (see Methods). Figure 1A shows that both fragments efficiently activated cytokine secretion by moDCs. In particular, we observed potent induction of proinflammatory cytokines (TNF- α , IL-6), the Th1-polarizing cytokine IL-12 and chemokines recruiting polymorphonuclear neutrophils (CXCL8), myelomonocytic cells (CCL3), and Th1- and cytotoxic effector cells (CXCL9). Especially at low concentrations, SCV2-RNA1 and SCV2-RNA2 were more efficient than HIV-1–derived RNA40. In all experimental conditions, U/A–alternated SCV2-RNA1A and SCV2-RNA2A did not induce cytokine secretion. SCV2-RNA1 and SCV2-RNA2 also induced moDC phenotypical maturation in terms of CD83, CD86, and CCR7 expression (Figure 1B). Similar to cytokine secretion, upregulation of maturation markers by RNA40 was less effective. These results demonstrated that SCV2-RNA1 and SCV2-RNA2 behaved as SAMPs endowed with potent DC stimulatory capacity. Because of their similar potency, further experiments were carried out using a mixture of the 2 SAMPs (indicated as SCV2-RNA), a condition that may also better mimic physiological stimulation by multiple sequences derived from SARS-CoV-2 genome endosomal fragmentation.

ssRNA SAMPs activate T cell responses. The impact of SAMPs on the ability of DCs to stimulate T cell functions was investigated in coculture experiments of SAMP-activated DCs with allogeneic naive CD4⁺ and CD8⁺ T cells. Figure 2A shows that SAMP-activated DCs induced proliferation of naive CD4⁺ and CD8⁺ T cells. Activated CD4⁺ T cells produced IFN- γ but no IL-4, a typical Th1-effector phenotype (Figure 2B). Functional activation of CD8⁺ T cells was similarly demonstrated by the detection of secreted IFN- γ (Figure 2C) and the intracellular accumulation of granzyme B, a marker of a cytotoxic phenotype. None of these effects were observed when DCs were activated with U/A–alternated SAMPs.

These experiments demonstrated that phenotypical DC maturation induced by SAMPs (Figure 1B) was paralleled by the acquisition of T cell–activating capabilities. Thus, SAMPs have the ability to induce a Th1-oriented immune response.

ssRNA SAMPs activate human primary DCs. The ability of SCV2-RNAs to activate DCs was further investigated using primary circulating cDCs (comprising CD141⁺ cDC1 and CD1c⁺ cDC2) and BDCA2⁺ pDCs. SCV2-RNA efficiently induced the secretion of TNF- α and IL-6 (Figure 3A) and the expression of maturation markers, such as CD86 and CCR7 (Figure 3B), in cDCs. Similarly, SAMPs stimulated the release of IFN- α and TNF- α by pDCs (Figure 3C) as well as their maturation in terms of CD86 upregulation and BDCA2 reduction (Figure 3D). Similar to previous results, U/A–alternated control sequences did not activate cytokine production or maturation in either pDCs or cDCs (not shown).

ssRNA SAMPs activate the TLR8/MyD88/NF- κ B axis in moDCs. The cellular sensors responsible for SARS-CoV-2 detection by immune cells remain ill defined. To formally demonstrate the ability of SAMPs




Figure 1. SAMPs activate cytokine secretion and phenotypical maturation of moDCs. (A) moDCs (2×10^6 /mL) were stimulated with increasing concentrations of the indicated viral RNAs or with vehicle alone (-) for 24 hours. The production of TNF- α , IL-6, IL-12p70, CXCL8, CCL3, and CXCL9 was evaluated by ELISA in cell-free supernatants. Data are expressed as mean \pm SEM ($n = 3$). Results of SCV2-RNA1A and SCV2-RNA2A are superimposed in all graphs. (B) moDCs were stimulated as described in A and the surface expression of CD83, CD86, and CCR7 evaluated by FACS analysis. Data are expressed as representative cytofluorimetric profiles (upper panels) or as the mean \pm SEM ($n = 3$) of the MFI (lower panels). (A and B) * $P < 0.05$ versus (-) by 1-way ANOVA with Dunnett's post hoc test; # $P < 0.05$ versus RNA40 by paired Student's t test.

to functionally activate TLRs, experiments were performed in HEK293 cells stably transfected with human TLR7 and TLR8 together with an NF- κ B reporter gene. Figure 4A depicts the SAMP-dependent activation of NF- κ B and luciferase production in TLR7- and TLR8-expressing cells. NF- κ B activation was also detected in SCV2-RNA-stimulated moDCs (Figure 4B). Since both TLR7 and TLR8 signal through the common adaptor MyD88, siRNA interference was performed in moDCs. Figure 4C shows that MyD88-specific siRNA could decrease by about 50% the levels of MyD88 mRNA, whereas the expression of the TLR3-related




Figure 2. SAMP-activated DCs trigger T cell proliferation and functional activation. (A) moDCs were stimulated with vehicle (-) or with SCV2-RNA or the A-to-U-replaced SCV2-RNA-A (both at 5 μg/mL) for 24 hours. Activated moDCs were cocultured for 6 days with CFSE-stained allogenic naive CD4⁺ T cells or CD8⁺ T cells at the indicated DC/T cell ratio. Alloreactive T cell proliferation was assessed by measuring CellTrace-CFSE dye loss by flow cytometry. Data are expressed as mean ± SEM (n = 3) of the percentage of proliferating T cells. (B) moDCs stimulated as in A were cocultured for 6 days with allogenic naive CD4⁺ T cells (DC/T cell ratio 1:20). Intracellular IFN-γ and IL-4 were evaluated by FACS analysis. Left, dot plots from 1 representative experiment out of 4 are shown. Right, bar graphs from 4 independent experiments. Data are expressed as mean ± SEM of the percentage of IFN-γ-producing cells. (C) moDCs activated as in A were cocultured for 6 days with allogenic CD8⁺ T cells (DC/T cell ratio 1:10). IFN-γ production was evaluated by ELISA in cell-free supernatants and intracellular granzyme B (GrB) by FACS analysis. Data are expressed as mean ± SEM (n = 3). (A-C) *P < 0.05 versus (-) by 1-way ANOVA with Dunnett's post hoc test.

adaptor TRIF and RLR-related MAVS was not affected. Consistent with this result, IL-6 production by SCV2-RNA was also decreased, supporting a role for MyD88 in moDC activation by SCV2-RNA (Figure 4C). Because SAMPs, despite being designed to activate TLR7/8, may also engage other pattern recognition receptors (PRRs) expressed by moDCs, we also performed TRIF and MAVS siRNA interference. Although siRNAs efficiently and specifically inhibited the expression of target genes (Figure 4C), they failed to reduce




Figure 3. SAMPs activate cytokine secretion and phenotypical maturation in primary circulating DC subsets. cDCs (2×10^6 /mL) and pDCs (1×10^6 /mL) were stimulated with 5 μ g/mL SCV2-RNA for 24 hours. (A–C) Cytokine secretion was evaluated by ELISA. Data are expressed as mean \pm SEM ($n = 3$ –4); * $P < 0.05$ versus (-) by paired Student’s t test. (B–D) Surface expression of CD86, CCR7, and BDCA2 was evaluated by FACS analysis. Data are expressed as mean \pm SEM of the MFI (left y axis), as well as the mean \pm SEM of the percentage of positive cells (right y axis) ($n = 3$ –4); * $P < 0.05$ versus (-) by paired Student’s t test.

IL-6 production by SCV2-RNA (Figure 4C). The predominant role of the MyD88/NF- κ B pathway as compared with that of TRIF/MAVS/IRF-3 was also supported by the lack of SCV2-RNA-dependent induction of nuclear translocation of IRF-3, a transcription factor downstream of TLR3 and RLRs (not shown).

moDCs are known to respond mainly to TLR8 ligands and to express negligible levels of TLR7 mRNA (14, 23). mRNA and protein expression analysis of TLR7 and TLR8 confirmed selective expression of TLR8 in our experimental setting (Supplemental Figure 1, A and B). Based on this, we performed TLR8 siRNA in moDCs, showing a reduction in SCV2-RNA-dependent activation correlating to the levels of mRNA reduction (Figure 4D).

Next, moDCs were stimulated in the presence of CU-CPT9a, a specific TLR8 inhibitor (26). CU-CPT9a inhibited both NF- κ B nuclear translocation (Figure 4E) and IL-6 production when cells were stimulated with SCV2-RNA or R848 (TLR7/8 ligand; Figure 4F). On the other hand, the TLR8 inhibitor did not affect the




Figure 4. SAMPs activate the TLR8/MyD88/NF-κB axis in moDCs. (A) HEK293 cells stably transfected with human TLR7, TLR8, or luciferase alone (-) were stimulated with SCV2-RNA for 24 hours. NF-κB activation was evaluated as luciferase activity. Data are expressed as mean ± SEM (n = 3); *P < 0.05 versus (-) by 1-way ANOVA with Dunnett's post hoc test. (B-E) moDCs were stimulated with SCV2-RNA as indicated (B) or pretreated with CU-CPT9a (1 μM) and then stimulated with SCV2-RNA or LPS for 1 hour (E). Nuclear extracts were blotted against NF-κB p65 and lamin B. One representative donor and densitometry of 3 donors are shown. *P < 0.05 versus untreated by 1-way ANOVA with Dunnett's post hoc test; #P < 0.05 versus "SCV2-RNA" by paired Student's t test. (C, left panel) moDCs were transfected with indicated siRNAs and target gene expression evaluated by qPCR. Results depict percentage of target gene expression (mean ± SEM n = 4). (C, right panel) moDCs transfected with indicated siRNAs were stimulated with SCV2-RNA for 24 hours and IL-6 production evaluated by ELISA. Data are expressed as percentage of production (n = 4); *P < 0.05 versus "ctr siRNA" by 1-way ANOVA with Dunnett's post hoc test. (D) moDCs were transfected with indicated siRNAs and the expression of TLR8 was evaluated by qPCR (left y axis, white bars). IL-6 production upon SCV2-RNA stimulation was evaluated by ELISA (right y axis, gray bars). Data (percentage of expression/production) represent the mean ± SEM (n = 3); *P < 0.05 versus respective "ctr" by paired Student's t test. (F) moDCs were pretreated with CU-CPT9a, then stimulated as indicated for 24 hours and IL-6 production evaluated by ELISA. Data are expressed as percentage of production for each individual stimulation (n = 3); *P < 0.05 versus respective "0" by 1-way ANOVA with Dunnett's post hoc test.

stimulation by LPS, a TLR4 ligand (Figure 4, E and F). Finally, we found that SCV2-RNA colocalized with TLR8 within moDCs (Supplemental Figure 1C).

ssRNA SAMPs act as TLR7/8 ligands in primary DCs. TLR7 and TLR8 display a mutually exclusive expression in primary DCs. Indeed, cDCs express TLR8 as their unique endosomal ssRNA receptor, whereas pDCs express TLR7 (14). Consistent with this, CU-CPT9a blocked the production of proinflammatory cytokines in cDCs (Figure 5A) but not in TLR7-expressing pDCs (Figure 5B). Our effort to block TLR7




Figure 5. TLR7 and TLR8 are responsible for primary DC activation by SAMPs. cDCs (A) and pDCs (B) were pretreated with increasing concentration of CU-CPT9a and then stimulated with SCV2-RNA (5 $\mu\text{g}/\text{mL}$) for 24 hours. Secreted TNF- α , IL-6, and IFN- α were quantified by ELISA. Data are expressed as percentage of production ($n = 3$); $*P < 0.05$ versus "0" by 1-way ANOVA with Dunnett's post hoc test. (C) pDCs were pretreated (0 hours) with SCV2-RNA (5 $\mu\text{g}/\text{mL}$) or R848 (1 $\mu\text{g}/\text{mL}$) or left untreated for 24 hours, washed, and restimulated with R848 for an additional 24 hours. Secreted IFN- α and TNF- α were quantified by ELISA. Data are expressed as mean \pm SEM ($n = 3$); $*P < 0.05$ versus "-" by 1-way ANOVA with Dunnett's post hoc test. (D) cDCs were pretreated for 1 hour with chloroquine (CQ, 10 μM) and then stimulated with SCV2-RNA (5 $\mu\text{g}/\text{mL}$) for 24 hours. Secreted IL-6 (white bars) and TNF- α (gray bars) were evaluated by ELISA. Data are expressed as percentage of production ($n = 3$); $*P < 0.05$ versus respective "-" SCV2-RNA" by paired Student's t test. (E) pDCs were pretreated for 1 hour with CQ (10 μM) and then stimulated with SCV2-RNA (5 $\mu\text{g}/\text{mL}$) for 24 hours. Secreted IFN- α (white bars) and TNF- α (gray bars) were quantified by ELISA. Data are expressed as percentage of production ($n = 3$); $*P < 0.05$ versus respective "-" SCV2-RNA" by paired Student's t test.

signaling using commercially available receptor antagonists was unsuccessful since none of these inhibitors blocked TLR7 activation in pDCs stimulated with R848 or imiquimod (data not shown). As an alternative strategy to demonstrate the involvement of TLR7 in SCV2-RNA sensing, we performed TLR desensitization (21). pDCs were stimulated with SCV2-RNA or R848 or left untreated, washed, and then restimulated with R848. Figure 5C shows that upon restimulation, only untreated cells could respond to R848 in terms of IFN- α and TNF- α production as a result of TLR7 desensitization by its ligand R848 as well as by SCV2-RNA. The limited yield after blood DC purification hampered the use of siRNAs. However, the involvement of endosomal TLRs as SCV2-RNA receptors was further supported by the blocking of cytokine release in cDCs (Figure 5D) and pDCs (Figure 5E) by chloroquine, a drug known to block endosomal TLR triggering by interfering with endosomal acidification (27).

ssRNA SAMPs induce DC activation and lung inflammation in vivo. To address the capacity of SAMPs to induce inflammation and immune activation in vivo, we first investigated whether SAMPs can also trigger murine TLR7, the only GU-rich ssRNA-sensing TLR in mice (20). Murine TLR7 activation by SAMPs could be hypothesized based on previous studies demonstrating activation of human TLR7/8 and murine TLR7 by common GU-rich ssRNA ligands (20, 28). In support of this, we showed that TLR7-expressing RAW264.7 cells (Figure 6A) responded to SAMP stimulation by producing TNF- α , an effect that was reduced by chloroquine pretreatment (Figure 6B), confirming that SCV2-RNA activated murine cells, presumably via TLR7. In addition, splenocytes from MyD88 $^{-/-}$ mice did not respond to SCV2-RNA stimulation either in terms of proinflammatory cytokine production (Figure 6D) or TLR modulation (Supplemental Figure 2), despite expressing similar levels of TLRs as compared with WT mice (Figure 6C).

Based on these results, C57Bl6/J WT and MyD88 $^{-/-}$ mice were i.v. injected with SAMPs or vehicle and euthanized 6 hours later. A significant increase of type I IFN was detected in the sera of WT SAMP-treated




Figure 6. SAMPs activate murine cells in vitro and in vivo. (A) Expression of *TLR* mRNAs in RAW264.7 cells. Data are expressed as $2^{-\Delta Ct}$ relative to RPL32 of 1 representative experiment out of 3. (B) RAW264.7 (1×10^6 /mL) were pretreated for 1 hour with CQ (12.5 μ M), then stimulated with 5 μ g/mL SCV2-RNA or vehicle (-) for 24 hours. Secreted TNF- α was evaluated by ELISA. Data are expressed as mean \pm SEM ($n = 3$); * $P < 0.05$ versus (-); $\ddagger P < 0.05$ versus “(-) SCV2-RNA” by paired Student’s *t* test. (C) Expression of *TLR* mRNAs in splenocytes from WT (white circle) or MyD88^{-/-} mice (black circle). Data are expressed as mean \pm SEM ($n = 3$) of $2^{-\Delta Ct}$ relative to RPL32 of 1 representative experiment out of 3. (D) Splenocytes (3×10^6 /mL) from WT (white circle) or MyD88^{-/-} mice (black circle) were stimulated with 5 μ g/mL SCV2-RNA or vehicle (-) for 24 hours. Secreted TNF- α was evaluated by ELISA. Data are expressed as mean \pm SEM ($n = 3$); * $P < 0.05$ versus (-) or $\#P < 0.05$ versus “SCV2-RNA MyD88^{-/-}” by paired Student’s *t* test. (E) Circulating IFN- α in WT (white circle) or MyD88^{-/-} mice (black circle) treated with SCV2-RNA or vehicle (-) for 6 hours. Data are expressed as mean \pm SEM [(-) $n = 4$, SCV2-RNA $n = 7$]; * $P < 0.05$ versus (-) or $\#P < 0.05$ versus “SCV2-RNA MyD88^{-/-}” by unpaired Student’s *t* test. of 1 representative experiment out of 3. (F–H) Activation of splenic pDCs (CD11c^{int}MHC-II⁺B220⁺SiglecH⁺) (F), cDC1s (CD11c⁺MHC-II⁺CD8 α CD11b⁺) (G), or cDC2s (CD11c⁺MHC-II⁺CD8 α CD11b⁺) (H) from WT (white circle) or MyD88^{-/-} mice (black circle), treated with SCV2-RNA or vehicle (-) for 6 hours evaluated in terms of CD40 and CD86 expression. Data are expressed as mean \pm SEM of the MFI [(-) $n = 4$, SCV2-RNA $n = 7$]; * $P < 0.05$ versus (-) or $\#P < 0.05$ versus “SCV2-RNA MyD88^{-/-}” by unpaired Student’s *t* test.

mice, indicating systemic immune activation (Figure 6E). Consistent with this, SAMPs induced the upregulation of CD40 and CD86 on splenic pDCs (CD11c^{int}MHC-II⁺B220⁺SiglecH⁺; Figure 6F). Activation of splenic cDC1s (CD11c⁺MHC-II⁺CD8 α CD11b⁺) and cDC2s (CD11c⁺MHC-II⁺CD8 α CD11b⁺) was also detected (Figure 6, G and H). Figure 7A shows that SAMP treatment induced the expression of proinflammatory cytokines TNF- α , IL-1 β , and IL-6 and of IFN- α and IFN- γ in the lung. In addition, a marked increase in the expression of chemokines active on myeloid and Th1-effector cells (i.e., CCL3, CCL4, and CXCL10) was also detected. Conversely, CCL20 and CCL22, 2 chemokines active in Th17 and Th2 T cell recruitment, were not increased (Figure 7B). We could also detect the accumulation of molecules involved in cytotoxic tissue damage such as granzyme B and TRAIL (Figure 7C) that, given the short kinetics of stimulation, may reflect the recruitment of NK cells to the lungs. The increase in CD45 and MHC-II levels (data not shown) further suggested immune cell infiltration, which was confirmed by histological analysis. Lung histology revealed a




Figure 7. SAMPs induce inflammation in vivo. (A–C) Real-time PCR for cytokines, chemokines, and effector proteins in lungs of WT (white circle) or MyD88^{-/-} (black circle) treated or not with SCV2-RNA for 6 hours. Data are expressed as mean \pm SEM [(-) $n = 4$, SCV2-RNA $n = 7$] of $2^{-\Delta\Delta Ct}$ relative to house-keeping mRNA (*RPL32*); * $P < 0.05$ versus (-) or # $P < 0.05$ versus “SCV2-RNA MyD88^{-/-}” by unpaired Student’s *t* test of 1 representative experiment out of 3. (D) Histological evaluation of lungs from WT or MyD88^{-/-} mice treated or not with SCV2-RNA for 6 hours. Image shows 1 section out of the 3 longitudinal serial sections performed of 1 representative left lung out of 7. Scale bars: 100 μ m.

marked infiltration of inflammatory cells into peribronchial and perivascular connective tissue and alveolar septal thickening in SAMP-treated mice (Figure 7D). On the contrary, SAMP administration to MyD88^{-/-} mice did not induce any inflammatory response, including the increase of circulating levels of type I IFN, DC maturation, and the generation of a lung infiltrate (Figure 6, D–H, and Figure 7). These data extend to the in vivo condition the observation that SAMPs use a TLR/MyD88-dependent pathway to trigger a type I IFN/proinflammatory activation program and highlight the lung as a primary target organ.

Discussion

Here, we report that 2 short sequences within the ssRNA genome of SARS-CoV-2 activate the production of type I IFNs and the T cell-activating ability of human DCs by triggering endosomal TLR7 and TLR8.

Of note, these sequences represent prototypical examples of the several hundreds of potential TLR ligands identified by SARS-CoV-2 genome scan. This finding is in line with previous work demonstrating a 20-fold higher density of GU-rich fragments in the closely related SARS-CoV as compared with HIV-1 (29) and with a recent bioinformatic study showing that SARS-CoV-2 encodes a number of such fragments even larger than SARS-CoV (30). Thus, endosomal processing of SARS-CoV-2 nucleic acids may give rise to multiple fragments endowed with the property to trigger innate immune activation.

TLR7/8 are sensors of ssRNA viruses including coronaviruses. In the past, TLR7-dependent recognition of MERS-CoV and human and murine pDC activation was demonstrated (31). In addition, murine coronavirus activated protective type I IFN production by TLR7-expressing murine pDCs (32), and the ssRNA SARS-CoV genome was shown to induce TLR7/8-dependent cytokine secretion by human PBMCs and RAW264.7 murine cells (29). By contrast, the involvement of TLR7/8 in the immune response against SARS-CoV-2 and role in COVID-19 pathogenesis and therapeutic potential has only been hypothesized (33). Notably, very rare loss-of-function variants of TLR7 in 2 independent families were associated with severe COVID-19 in males (34). Thus, our report on the ability of SAMPs to activate the TLR7/8 and MyD88 pathways provides the missing link between clinical evidence and molecular knowledge on the cellular sensors for SARS-CoV-2 detection. Viral recognition by endosomal TLRs takes place before and independently of infection as a consequence of pathogen endocytosis (13). Indeed, pDCs were reported to be resistant to infection, although they were activated by SARS-CoV-2 (35). This is an important process that gives innate immune cells the opportunity to activate early antiviral response. One limitation of our experimental approach is that it does not shed light on the actual triggering of endosomal TLRs during active SARS-CoV-2 infection. However, this is a likely event based on the reported SARS-CoV-2-dependent pDC activation, which uses TLR7 as the main ssRNA receptor (12, 35). In addition, endosomal TLRs expressed by innate immune cells were shown to be activated by viral RNAs packaged within extracellular vesicles by infected tissue cells (36), a mechanism that is mimicked by SCV2-RNA delivery by liposomal particles. Indeed, in another experimental setting, liposome-delivered ssRNA40 from HIV-1 activated human macrophages via TLR8 in a way that recapitulated intact HIV-1 administration (37). It remains to be elucidated whether SARS-CoV-2 uptake for endosomal processing is a direct process or mediated by receptors, such as ACE2 or CD147 (38).

DCs are heterogeneous cells that master activation of inflammation and antiviral responses, adaptive immune responses, and tolerance (7, 8). These functions are largely shared among different phenotypical and functional DC subsets (39). Indeed, pDCs are the major producers of type I IFNs in response to viral infections (10–12), while cDCs, and cDC2s in particular, sustain inflammation via cytokine secretion and activate naive T cells (39). Notably, this specialization mirrors the respective expression and function of TLR7 and TLR8 (14). The protective role of TLR7 and type I IFNs in life-threatening COVID-19 has been documented based on the clinical outcome of patients with inborn errors in type I IFN immunity, producing blocking autoantibodies against different types of type I IFNs (5, 6) or expressing loss-of-function variants of TLR7 (34). Therefore, SAMPs may represent one of the essential signals in the activation of an IFN response and Th1-oriented adaptive immunity (40, 41). In this regard, it is of note that SARS-CoV-2 infection affected the number of pDCs in vivo (17, 18) and primary virus isolates induced the activation of pDCs in vitro (35). By contrast, an aggravated inflammatory response causes damage to the host and frequently advances to acute respiratory distress syndrome in patients with severe COVID-19. Here, we showed that the activation program induced by SAMPs was not restricted to type I IFNs but encompassed the production of proinflammatory cytokines and the generation of Th1-oriented responses, which may contribute to the exuberant proinflammatory response observed in life-threatening COVID-19 (42). Whether TLR8 or cDC overactivation or genetic variants are involved in this process is difficult to speculate, and more studies on selected patient cohorts are needed. However, TLR7 and TLR8 selective agonists or antagonists, inducing antiviral IFN response and/or controlling inflammation, deserve consideration and have entered phase II clinical trials as interesting therapeutic options to control the different manifestations of COVID-19 (ClinicalTrials.gov NCT04448756). ssRNA-sensing TLRs are expressed by cells other than DCs, such as macrophages, and by peripheral tissues, such as the lung, bronchus, rectum, and cerebral cortex (38). Thus, other cells may contribute to the complex balance of protective versus detrimental immune activation (4). Finally, since the magnitude of TLR activation differs in individuals, such as elderly people, differences in TLR activation may help explain differences in the quality of the antiviral immune response independently of SAMP potency (39).

By all means, other SAMPs and damage-associated molecular patterns (DAMPs) as well as the simultaneous engagement of different PRRs are likely to contribute to COVID-19-associated protective response and

cytokine storm, including cytosolic sensors, such as retinoid-inducible gene-I-like receptors (43), IFN-induced proteins with tetratricopeptide repeats, or members of a large group of RNA-binding molecules with poorly defined ligand specificity (43). A search for specific candidate ligands of cytosolic RNA sensors was hampered because of the scarce definition of their ligand consensus sequences. However, the finding that SARS-CoV-2 can evade innate immune restriction provided by intracellular RNA sensors via methylation of the 5' end of its cellular mRNAs (44) further reinforces the role for TLRs as crucial sentinels and regulators of immune response to SARS-CoV-2 infection. SARS-CoV-2 is known to induce inflammasome assembly, although the exact mechanism still needs to be characterized (45, 46). Since intracellular nucleic acid sensors are known to activate inflammasomes (47), and TLR activation is intimately connected with inflammasome functions (48, 49), it is possible that SCV2-RNAs used in this study may also contribute to activation of this pathway.

In conclusion, this work has described SARS-CoV-2 as a potential powerful source of immunostimulatory nucleic acid fragments and has identified SARS-CoV-2-specific pathogen-associated molecular patterns (PAMPs) endowed with the ability to promote inflammation and immunity triggering TLR7 and TLR8. Based on previous studies demonstrating a) the crucial protective role of type I IFNs against COVID-19 (5, 6), b) the crucial protective role of TLR7 against life-threatening SARS-CoV-2 infection (34), and c) pDC activation *in vitro* by SARS-CoV-2 (35), we believe that our findings fill a gap in the understanding of SARS-CoV-2 host-pathogen interaction.

Methods

Identification of potential TLR7/8-triggering ssRNA PAMPs. The reference SARS-CoV-2 genome (NC_045512, positive strand) was scanned for GU-rich ssRNA fragments with the SequenceSearcher tool in the Fuzzy mode (50). We defined “GU-enriched sequences” as short strings with a maximal length of 20 bp that were composed of GU and/or UG pairs for more than 40% of their length. The identified 491 GU-rich sequences were further selected based on the content of at least 1 UGUGU IIM (ref. 21; see Supplemental Table 1). Within this list, the following were selected based on the particular enrichment in IIM (21) and synthesized by Integrated DNA Technologies (IDT) for subsequent studies: SCV2-RNA1 5'-UGCUGUUGU-GUGUU*U-3' (genome position: 15692-15706); SCV2-RNA2 5'-GUGUGUGUGUUCUGUUAUU*G-3' (genome position: 20456-20475; *indicates a phosphorothioate linkage). These sequences were checked for uniqueness with BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome) selecting RNA viruses (taxid: 2559587) as organism in the “search set” window”. Two additional sequences were synthesized in which U was substituted with A in order to impair TLR7/8 stimulation (SCV2-RNA1A and SCV2-RNA2A; refs. 15, 20).

Cell preparation and culture. PBMCs were obtained by density gradient centrifugation and monocytes were subsequently purified by immunomagnetic separation using anti-CD14-conjugated magnetic microbeads (Miltenyi Biotec) according to the manufacturer's protocol and as previously published (23). Briefly, monocytes were cultured for 6 days in tissue culture plates in complete medium (RPMI 1640 supplemented with 10% heat-inactivated, endotoxin-free FBS, 2 mM L-glutamine, penicillin, and streptomycin; all from Gibco, Thermo Fisher Scientific) in the presence of 50 ng/mL GM-CSF and 20 ng/mL IL-4 (Miltenyi Biotec). Untouched peripheral blood cDC1 and cDC2 (cDCs) and pDCs were obtained from PBMCs after negative immunomagnetic separation with the Myeloid Dendritic Cell Isolation kit (Miltenyi Biotec) and the Plasmacytoid Dendritic Cell Isolation kit II (Miltenyi Biotec), respectively. pDCs were cultured in completed RPMI medium with 20 ng/mL IL-3 (Miltenyi Biotec). RAW264.7 cells were purchased from American Type Culture Collection (ATCC) and cultured in DMEM complemented with 10% FBS.

Cell stimulation. Complexation of RNA with DOTAP Liposomal Transfection Reagent (Roche) was performed as previously described (21). Briefly, 5 µg RNA (either SCV2-RNA1 alone, SCV2-RNA2 alone, or 2.5 µg SCV2-RNA1 + 2.5 µg SCV2-RNA2 to obtain SCV2-RNA) in 50 µL HBS buffer (20 mM HEPES, 150 mM NaCl, pH 7.4) was combined with 100 µL DOTAP solution (30 µL DOTAP plus 70 µL HBS buffer) and incubated for 15 minutes at room temperature. Where indicated, cells were pretreated for 1 hour with chloroquine or CU-CPT9a or stimulated with the following TLR agonists: LPS (100 ng/mL) and R848 (1 µg/mL) (all from InvivoGen).

siRNA silencing in moDCs. Differentiating monocytes at day 2 of culture were transfected with MyD88 or TRIF or MAVS or TLR8 Silencer Select Validated siRNA or with a control siRNA (all at 50 nM final concentration; Ambion, Thermo Fisher Scientific) using Opti-MEM I reduced serum medium and Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) as previously described (51). Transfected cells

were incubated for 72 hours and then stimulated for 24 hours with SCV2-RNA. The effects of mRNA silencing by siRNA were investigated by quantitative PCR (qPCR) using specific QuantiTect primer assay (Qiagen).

Cytokine detection. TNF- α , IL-6, IL-12p70, CXCL8, CXCL9, CCL3, and mouse TNF- α were measured by ELISA (R&D Systems). Human IFN- α was detected using specific Module Set ELISA kit (eBioscience). Mouse IFN- α was measured by a bioluminescence kit (InvivoGen). All assays were performed on cell-free supernatants according to the manufacturer's protocol.

Flow cytometry. Human and mouse DCs were stained with the following antibodies from Miltenyi Biotec or as specified: Vioblue-conjugated anti-human CD86 (clone FM95), PE-conjugated anti-human CD83 (clone REA714), FITC-conjugated anti-human BDCA2 (clone AC144), APC-conjugated anti-human CCR7 (clone REA546), VioGreen-conjugated anti-mouse CD45 (clone REA737), VioBlue or FITC-conjugated anti-mouse MHC-II (clone REA564), PerCP-Vio 700-conjugated anti-mouse CD11c (clone REA754), PE-conjugated anti-mouse SiglecH (clone 551.3D3), PE-Vio 615-conjugated anti-mouse CD11b (clone REA592), VioBlue-conjugated anti-mouse CD8a (clone REA601), PE-Vio 770-conjugated anti-mouse B220 (clone RA3-6B2), APC-conjugated anti-mouse CD3 (clone REA641), APC-conjugated anti-mouse CD19 (clone REA749), APC-conjugated anti-mouse CD49b (clone DX5), APC-conjugated anti-mouse Ly6G (clone REA526), PE-conjugated anti-mouse CD40 (clone REA965), FITC-conjugated anti-mouse CD40 (clone HM40-3, BioLegend), and APC-CY7-conjugated anti-mouse CD86 (clone GL-1, BioLegend). Samples were read on a MACSQuant Analyzer (Miltenyi Biotec) and analyzed with FlowJo (Tree Star Inc.). For intracellular detection of granzyme B, cells were fixed and permeabilized using the Inside Stain kit (Miltenyi Biotec) and stained with APC-conjugated anti-granzyme B (clone REA226, Miltenyi Biotec). Cell viability was assessed by LIVE/DEAD staining according to the manufacturers' instructions (Molecular Probes, Thermo Fisher Scientific). The gating strategy of mouse DCs was as follows: cells were first defined from FSC-A/SSC-A over doublet exclusion and gating on live CD45⁺ LIN⁻ cells (defined as CD3/CD19/CD49b/Ly6G⁻). Therefore, pDCs were identified as CD11c^{int}MHC-II⁺B220⁺SiglecH⁺ cells; cDC1s as CD11c⁺MHC-II⁺CD8 α ⁺CD11b; cDC2s as CD11c⁺MHC-II⁺CD8 α CD11b⁺ (52).

NF- κ B luciferase reporter assay. TLR-specific activation assays were performed using human HEK293 cells (ATCC) expressing luciferase under control of the NF- κ B promoter and stably transfected with human TLR7 and TLR8 as previously described (21). Briefly, 25,000 cells were seeded in complete DMEM without antibiotics in 96-well plates for 24 hours and then stimulated with 10 μ g/mL SCV2-RNA for an additional 24 hours. After stimulation, cells were lysed using ONE-Glo EX Luciferase Assay System (Promega) according to the manufacturer's recommendations and assayed for luciferase activity using the EnSight Multimode Plate Reader (PerkinElmer). HEK293 cells were maintained in DMEM supplemented with 10% FBS and specific selection antibiotics were added.

SDS-PAGE and Western blot. Following the indicated stimulations, moDCs were washed twice with PBS and lysed in L1 buffer (50 mM Tris-HCl, pH 8.0; 2 mM EDTA; 0.1% NP-40; 10% glycerol) supplemented with inhibitors (1 mM Na₃VO₄, 2 mM DTT, 1 mM NaF, 1 mM PMSF, and protease inhibitor cocktail; all from MilliporeSigma) to separate cytoplasmic proteins. Nuclear pellets were washed twice with L1 buffer with inhibitors and then lysed in NP-40 lysis buffer (50 mM Tris-HCl, pH 8.0; 250 mM NaCl; 1 mM EDTA; 0.1% NP-40; 10% glycerol) with inhibitors. For the analysis of TLR expression, moDCs and HEK293-transfected cells were lysed in NP-40/Triton X-100 lysis buffer (10 mM Tris-HCl, pH 7.9; 150 mM NaCl; 0.6% NP-40; and 0.5% Triton X-100) supplemented with inhibitors. Equal amounts of extracts were analyzed through SDS-PAGE followed by Western blotting with antibodies against NF- κ B p65 (rabbit polyclonal, C-20, sc-372, Santa Cruz Biotechnology), lamin B (goat polyclonal, C-20, 6216, Santa Cruz Biotechnology), TLR7 (rabbit monoclonal, 5632, Cell Signaling Technology), TLR8 (rabbit monoclonal, 11886, Cell Signaling Technology), and β -actin (mouse monoclonal, C4, sc-47778, Santa Cruz Biotechnology). Protein bands were detected with SuperSignal West Pico Chemiluminescent Substrate (Pierce) and quantified by computerized image analysis using Image Lab software (Bio-Rad). Data were normalized based on β -actin or lamin B content.

Immunofluorescence. moDCs were incubated with Atto-488-tagged SCV2-RNA1 (synthesized by Bio-Fab research) for 15 minutes, fixed with 4% paraformaldehyde (Pierce) for 10 minutes, and then seeded on glass slides by cytospin. After permeabilization with 100% cold methanol for 5 minutes, cells were labeled with a rabbit monoclonal anti-human TLR8 (11886, Cell Signaling Technology). A conjugate Alexa Fluor 594 anti-rabbit (A-11072, Thermo Fisher Scientific) was used as a secondary antibody. Glass slides were mounted using Prolong antifade with DAPI (Thermo Fisher Scientific). Cells were analyzed under a Zeiss Observer Z1 epifluorescence microscope equipped with a Plan-Apochromat 100 \times /1.4 numerical aperture oil objective and ApoTome2 imaging system for optical sectioning. Z-stack images were elaborated through AxioVision 3D and extended focus modules.

T cell proliferation assay. Experiments using T cells were conducted according to the “Minimal Information about T Cell Assays” (MIATA) guidelines. Allogeneic naive CD4⁺ T cells and CD8⁺ T cells were isolated from buffy coats using the naive CD4⁺ T cell isolation kit II (Miltenyi Biotec) and CD8⁺ T cell isolation kit (Miltenyi Biotec), respectively. Purified T cells were counted by flow cytometry and labeled with CellTrace-CFSE (Molecular Probes, Thermo Fisher Scientific) at a final concentration of 5 μ M. Subsequently, T cells (1×10^5 cells/well) were cocultured with graded numbers of allogeneic moDCs in 96-well round-bottom culture plates in complete RPMI medium. After 6 days, alloreactive T cell proliferation was assessed by measuring the loss of the dye CellTrace-CFSE upon cell division using flow cytometry. Positive controls of T cell proliferation were routinely performed using IL-2 plus phytohemagglutinin (PHA). Response definition criteria were defined post hoc. Dead cells were excluded by LIVE/DEAD staining according to the manufacturer’s instructions. These experiments were performed using general research investigative assays. Raw data can be provided upon request.

Analysis of T cell cytokine production. After 6 days of coculture, helper T cells were restimulated with 200 nM PMA (Sigma-Aldrich) plus 1 μ g/mL of ionomycin (Sigma-Aldrich) for 5 hours. Brefeldin A (5 μ g/mL, Sigma-Aldrich) was added during the last 2 hours. For intracellular cytokine production, cells were fixed and permeabilized with Inside Stain kit (Miltenyi Biotec) and stained with FITC-conjugated anti-IFN- γ (clone 45-15, Miltenyi Biotec) and PE-conjugated anti-IL-4 (clone 7A3-3, Miltenyi Biotec) following the manufacturer’s recommendations. For CD8⁺ T cells, after 6 days of coculture, IFN- γ production was assessed in the culture supernatants by ELISA (R&D Systems). Response definition criteria were defined post hoc. These experiments were performed using general research investigative assays. Raw data can be provided upon request.

In vivo experiments. MyD88^{-/-} mice (C57Bl6/J background) were provided by S. Akira (Laboratory of Host Defense, Immunology Frontier Research Center, Osaka University). WT C57Bl6/J mice were purchased from Charles River Laboratories. All mice were housed in the specific pathogen-free animal facility of the Department of Medicine, University of Verona. Sex- and age-matched WT and MyD88^{-/-} mice (8–10 weeks old) were anesthetized with isoflurane and i.v. injected in the retro-orbital vein with 300 μ L DOTAP/SCV2-RNA mixture (20 μ g/mouse) or with DOTAP alone. After 6 hours, mice were euthanized and lungs, spleen, and blood were harvested. Briefly, lungs were collected upon intracardiac perfusion with cold PBS. Left lung lobes were formalin-fixed for 24 hours, dehydrated, and paraffin-embedded for histological analysis. Right lungs were immediately frozen at -80°C and used for real-time PCR. Spleens were mechanically and enzymatically treated to obtain a single-cell suspension for cytofluorimetric and real-time PCR analysis.

Lung histological analysis. Histology was performed on 3 longitudinal serial sections (150 μ m apart, 4 μ m in thickness) from each left lung, stained with H&E, and scanned by VS120 Dot Slide BX61 virtual slide microscope (Olympus Optical) as previously described (53).

qPCR. RNA was extracted using TRIzol reagent and treated with DNase according to the manufacturer’s instructions, and reverse transcription was performed using random hexamers and Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV RT) (all from Thermo Fisher Scientific). The SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) was used according to the manufacturer’s instructions. Reactions were run in triplicate on a StepOne Plus Real-Time PCR System (Applied Biosystems) and analyzed by StepOne Plus Software (Version 2.3, Applied Biosystems). Sequences of gene-specific primers are listed in Supplemental Table 2. Gene expression was normalized based on mouse RPL32 or human hypoxanthine phosphoribosyltransferase (HPRT) mRNA content.

Statistics. Sample group normality was confirmed by Shapiro-Wilk test before application of parametric statistical analysis. Statistical significance among the experimental groups was determined using 2-tailed paired or unpaired Student’s *t* test or 1-way ANOVA with Dunnett’s post hoc test (GraphPad Prism 7) as indicated in each figure legend. *P* less than 0.05 was considered significant; *n* indicates the number of biological replicates and is specified in each figure legend.

Study approval. Buffy coats from blood donations of anonymous healthy donors were obtained and preserved by the Centro Trasfusionale, Spedali Civili of Brescia according to the Italian law concerning blood component preparation and analysis. Procedures involving animal handling and care conformed to protocols approved by the University of Verona in compliance with national (D.L. N.116, G.U., Supplemental 40, 18-2-1992 and N. 26, G.U. March 4, 2014) and international law and policies (EEC Council Directive 2010/63/EU, OJ L 276/33, 22-09-2010; NIH Guide for the Care and Use of Laboratory Animals, National Academies Press, 2011). The study was approved by the Italian Ministry of Health (approval 339/2015-PR). All efforts were made to minimize the number of animals used and their suffering.

Author contributions

DB, MAC, AM, SS, VS, and ADP contributed to conceptualization; VS, ADP, PS, DB, and C. Garlanda contributed to methodology; ML and DB contributed to software; VS, HON, MP, and IB performed validation and formal analysis; VS, HON, FS, TS, ML, PS, LT, IB, MP, NT, C. Gaudenzi, and C. Garlanda conducted the investigation; VS, HON, FS, ML, and IB curated data; DB, VS, and HON wrote the original draft; AM, SS, MAC, PS, ADP, and DB reviewed and edited the manuscript; HON and IB contributed to visualization; DB, MAC, and SS supervised the study; SS, MAC, DB, and PS acquired funding. All authors have read and agreed to the published version of the manuscript.

Acknowledgments


This research was funded by the Italian Ministry of Health (Bando Ricerca COVID-2020-12371735 to SS), Italian Ministry of the University and Research (MUR-PRIN 20178ALPCM_005 to DB and MUR-PRIN 20177J4E75_004 to MAC), Associazione Italiana per la Ricerca sul Cancro (AIRC IG-20339 to MAC and IG-20776 to SS), University of Verona (RBVR17NCNC to PS), and University of Brescia (Fondi Locali 2019 and 2020 to DB). AM acknowledges support from the Dolce & Gabbana fashion company. ML was the recipient of a fellowship from AIRC (code 25307).

Address correspondence to: Daniela Bosisio, University of Brescia, Viale Europa 11, 25123 Brescia, Italy. Phone: 39.030.3717700; Email: daniela.bosisio@unibs.it. Or to: Silvano Sozzani, Sapienza University of Rome, Viale Regina Elena 291, 00161 Roma, Italy. Phone: 39.06.49255115; Email: silvano.sozzani@uniroma1.it. Or to: Alberto Mantovani, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele Milano, Italy. Phone: 39.02.82242444,45,46; Email: alberto.mantovani@humanitasresearch.it.


1. Zhu N, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med.* 2020;382(8):727–733.
2. Guan W, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med.* 2020;382(18):1708–1720.
3. Liu F, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. *J Clin Virol.* 2020;127:104370.
4. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nat Rev Immunol.* 2020;20(6):355–362.
5. Zhang Q, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science.* 2020;370(6515):eabd4570.
6. Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science.* 2020;370(6515):eabd4585.
7. Cabeza-Cabrerizo M, et al. Dendritic cells revisited. *Annu Rev Immunol.* 2021;39:131–166.
8. Sozzani S. Dendritic cell trafficking: more than just chemokines. *Cytokine Growth Factor Rev.* 2005;16(6):581–592.
9. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. *Nat Rev Immunol.* 2007;7(7):543–555.
10. Asselin-Paturel C, et al. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. *J Exp Med.* 2005;201(7):1157–1167.
11. Blanco P, et al. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. *Cytokine Growth Factor Rev.* 2008;19(1):41–52.
12. Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. *Nat Rev Immunol.* 2015;15(8):471–485.
13. Uematsu S, Akira S. Toll-like receptors and type I interferons. *J Biol Chem.* 2007;282(21):15319–15323.
14. Jarrossay D, et al. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. *Eur J Immunol.* 2001;31(11):3388–3393.
15. Shimizu T. Structural insights into ligand recognition and regulation of nucleic acid-sensing Toll-like receptors. *Curr Opin Struct Biol.* 2017;47:52–59.
16. Cervantes JL, et al. TLR8: the forgotten relative revindicated. *Cell Mol Immunol.* 2012;9(6):434–438.
17. Zhou R, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. *Immunity.* 2020;53(4):864–877.
18. Peruzzi B, et al. Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection. *Immunology.* 2020;161(4):345–353.
19. Sozzani S, et al. Trafficking properties of plasmacytoid dendritic cells in health and disease. *Trends Immunol.* 2010;31(7):270–277.
20. Heil F. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. *Science.* 2004;303(5663):1526–1529.
21. Salvi V, et al. Exosome-delivered microRNAs promote IFN- α secretion by human plasmacytoid DCs via TLR7. *JCI Insight.* 2018;3(10):e98204.
22. Diebold SS, et al. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. *Eur J Immunol.* 2006;36(12):3256–3267.
23. Salvi V, et al. TLR Signalling pathways diverge in their ability to induce PGE2. *Mediators Inflamm.* 2016;2016:5678046.
24. Hornung V, et al. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. *J Immunol.* 2002;168(9):4531–4537.
25. Muzio M, et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. *J Immunol Baltim.* 2000;164(11):5998–6004.
26. Zhang S, et al. Small-molecule inhibition of TLR8 through stabilization of its resting state. *Nat Chem Biol.* 2018;14(1):58–64.

27. Kužnik A, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. *J Immunol.* 2011;186(8):4794–4804.
28. Fabbri M, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. *Proc Natl Acad Sci.* 2012;109(31):E2110–E2116.
29. Li Y, et al. Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response. *Microbes Infect.* 2013;15(2):88–95.
30. Moreno-Eutimio MA, et al. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes. *Microbes Infect.* 2020;22(4–5):226–229.
31. Scheuplein VA, et al. High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus. *J Virol.* 2015;89(7):3859–3869.
32. Cervantes-Barragán L, et al. Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. *J Immunol.* 2009;182(2):1099–1106.
33. Dyavar SR, et al. Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic options. *Biomed Pharmacother.* 2021;141:111794.
34. van der Made CI, et al. Presence of genetic variants among young men with severe COVID-19. *JAMA.* 2020;324(7):663–673.
35. Onodi F, et al. SARS-CoV-2 induces human plasmacytoid pre-dendritic cell diversification via UNC93B and IRAK4 [preprint]. <https://doi.org/10.1101/2020.07.10.197343>. Posted on BioRxiv January 8, 2021.
36. Kouwaki T, et al. Extracellular vesicles deliver host and virus RNA and regulate innate immune response. *Int J Mol Sci.* 2017;18(3):666.
37. Campbell GR, et al. Human immunodeficiency virus type 1 Nef inhibits autophagy through transcription factor EB sequestration. *PLoS Pathog.* 2015;11(6):e1005018.
38. Wang K, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. *Signal Transduct Target Ther.* 2020;5(1):283.
39. Collin M, Bigley V. Human dendritic cell subsets: an update. *Immunology.* 2018;154(1):3–20.
40. Sharma NK, et al. Is a COVID-19 vaccine developed by nature already at work? *Med Hypotheses.* 2020;145:110335.
41. Borges RC, et al. Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. *Int Rev Immunol.* 2020;40(1–2):108–125.
42. Zhang Q, et al. Life-threatening COVID-19: defective interferons unleash excessive inflammation. *Med (N Y).* 2020;1(1):14–20.
43. Chow KT, et al. RIG-I and other RNA sensors in antiviral immunity. *Annu Rev Immunol.* 2018;36(1):667–694.
44. Viswanathan T, et al. Structural basis of RNA cap modification by SARS-CoV-2. *Nat Commun.* 2020;11(1):3718.
45. Toldo S, et al. Inflammasome formation in the lungs of patients with fatal COVID-19. *Inflamm Res.* 2021;70(1):7–10.
46. Rodrigues TS, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. *J Exp Med.* 2021;218(3):e20201707.
47. Xiao TS. The nucleic acid-sensing inflammasomes. *Immunol Rev.* 2015;265(1):103–111.
48. Becker CE, O'Neill LAJ. Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs. *Semin Immunopathol.* 2007;29(3):239–248.
49. Campbell GR, et al. SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway. *iScience.* 2021;24(4):102295.
50. Marass F, Upton C. Sequence Searcher: a Java tool to perform regular expression and fuzzy searches of multiple DNA and protein sequences. *BMC Res Notes.* 2009;2:14.
51. Salvi V, et al. Dual regulation of osteopontin production by TLR stimulation in dendritic cells. *J Leukoc Biol.* 2013;94(1):147–158.
52. Cossarizza A, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). *Eur J Immunol.* 2019;49(10):1457–1973.
53. Del Prete A, et al. The atypical receptor CCRL2 is essential for lung cancer immune surveillance. *Cancer Immunol Res.* 2019;7(11):1775–1788.


A



B




C




Supplemental Figure 1. TLR8 expression and SAMP colocalization in moDCs. (A) mRNA from moDCs at day 6 of culture was extracted to analyse the expression of TLR7 and TLR8 by qPCR. Data are expressed as mean \pm SEM (n=3) of $2^{-\Delta Ct}$ relative to HPRT. (B) moDCs and HEK293 cells stably transfected with human TLR7, TLR8 or luciferase alone (-) were lysed and the expression of TLR7, TLR8 and β -actin was determined by Western blot. One representative fluorogram out of three is shown. (C) moDCs were stimulated with SCV2-RNA-Atto 488 for 15 minutes. After fixation and permeabilization, moDCs were stained with anti-TLR8 mAb (red) and DAPI (blue). Image on the right shows the orthogonal z reconstruction elaborated with AxioVision 3D. White dots correspond to TLR8 colocalizing with SCV2-RNA. This representative image depicts results obtained in one donor out of three; scale bar: 5 μ m.

A



B



Supplemental Figure 2. SCV2-RNA stimulation affects TLR expression in WT mice. Expression of TLR mRNAs in splenocytes from WT (upper panel) or MyD88^{-/-} mice (lower panel) stimulated with SCV2-RNA for 6 hours. Data are expressed as mean \pm SEM ((-) n=4, SCV2-RNA n=7) of $2^{-\Delta Ct}$ relative to RPL32 of one representative experiment out of three. *P < 0.05 versus respective “(-)” by paired Student’s *t* test.

Supplemental Table 1

Sequence number	Sequence	Start	Stop
1	TTTAAAATCT TGTGT GGCTG	76	94
2	TAAAATCT TGTGT GGCTGTC	78	96
3	CTGTGT GGCTGTCACTCGG	84	102
4	TTGCCTTTGGAGGCT TGTGT	1476	1494
5	TGCCTTTGGAGGCT TGTGTG	1477	1495
6	GCCTTTGGAGGCT TGTGTGT	1478	1496
7	CCTTTGGAGGCT TGTGTGT T	1479	1497
8	CTTTGGAGGCT TGTGTGT TC	1480	1498
9	TTTGGAGGCT TGTGTGT TCT	1481	1499
10	TGGAGGCT TGTGTGT TCTCT	1483	1501
11	GAGGCT TGTGTGT TCTCTTA	1485	1503
12	GGCT TGTGTGT TCTCTTATG	1487	1505
13	GCT TGTGTGT TCTCTTATGT	1488	1506
14	C TGTGTGT TCTCTTATGTT	1489	1507
15	TGTGTGT TCTCTTATGTTG	1490	1508
16	GTGTGT TCTCTTATGTTGG	1491	1509
17	TGTGT TCTCTTATGTTGGT	1492	1510
18	TAAATTTTTGGCTT TGTGT	2314	2332
19	AAATTTTTGGCTT TGTGTG	2315	2333
20	AATTTTTGGCTT TGTGTGC	2316	2334
21	ATTTTTGGCTT TGTGTGCT	2317	2335
22	TTTTTGGCTT TGTGTGCTG	2318	2336
23	TTTTGGCTT TGTGTGCTGA	2319	2337
24	TTGGCTT TGTGTGCTGACT	2321	2339
25	GGCTT TGTGTGCTGACTCT	2323	2341
26	TT TGTGTGCTGACTCTATC	2326	2344
27	TGTGTGCTGACTCTATCAT	2328	2346
28	ATTGTACAGAAAG TGTGT T	2410	2428
29	AATGAGTTCGCC TGTGT TG	2870	2888
30	ATGAGTTCGCC TGTGT TGT	2871	2889
31	TGAGTTCGCC TGTGT TGTG	2872	2890
32	GAGTTCGCC TGTGT TGTGG	2873	2891
33	GTTCCGCC TGTGT TGTGGCA	2875	2893
34	C TGTGT TGTGGCAGATGC	2880	2898
35	TGTGT TGTGGCAGATGCTG	2882	2900
36	AAGTGGGTGGTAGT TGTGT	3558	3576
37	AGTGGGTGGTAGT TGTGT T	3559	3577
38	GTGGGTGGTAGT TGTGT TT	3560	3578
39	TGGGTGGTAGT TGTGT TTT	3561	3579
40	GGGTGGTAGT TGTGT TTTA	3562	3580
41	GGTGGTAGT TGTGT TTTAA	3563	3581
42	GTGGTAGT TGTGT TTTAAG	3564	3582
43	TGGTAGT TGTGT TTTAAGC	3565	3583
44	GTAGT TGTGT TTTAAGCGG	3567	3585
45	G TGTGT TTTAAGCGGACA	3570	3588
46	ATTCTTTAAGAGTT TGTGT	3744	3762
47	TTCTTTAAGAGTT TGTGT A	3745	3763
48	CTTTAAGAGTT TGTGT AGA	3747	3765
49	TTAAGAGTT TGTGT AGATA	3749	3767
50	AAGAGTT TGTGT AGATACT	3751	3769
51	GAGTT TGTGT AGATACTGT	3753	3771

Supplemental Table 1

52	AGTT TGTGT AGATACTGTT	3754	3772
53	GTT TGTGT AGATACTGTTTC	3755	3773
54	TT TGTGT AGATACTGTTTCG	3756	3774
55	TGTGT AGATACTGTTTCGC	3757	3775
56	ATTAATGCCTGTCT TGTGTG	4426	4444
57	TAATGCCTGTCT TGTGTGGA	4428	4446
58	ATGCCTGTCT TGTGTG GAAA	4430	4448
59	GCCTGTCT TGTGTG GAAACT	4432	4450
60	AGTCTTGAACGTGG TGTGT	5503	5521
61	TCTTGAACGTGG TGTGTAA	5505	5523
62	CGTGG TGTGT AAAACCTTGT	5512	5530
63	GTGG TGTGT AAAACCTTGTG	5513	5531
64	TGG TGTGT AAAACCTTGTGG	5514	5532
65	GG TGTGT AAAACCTTGTGGA	5515	5533
66	TGTGT AAAACCTTGTGGAC	5516	5534
67	TTTATTGCTACAAT TGTGT	6787	6805
68	TTATTGCTACAAT TGTGTA	6788	6806
69	ATCAACTTGTATGAT TGTGT	7483	7501
70	CAACTTGTATGAT TGTGTTA	7485	7503
71	AATTGGAAT TGTGT TAATT	7610	7628
72	TTGGAAT TGTGT TAATTGT	7612	7630
73	GGAAT TGTGT TAATTGTGA	7614	7632
74	GAAT TGTGT TAATTGTGAT	7615	7633
75	AAT TGTGT TAATTGTGATA	7616	7634
76	ATT TGTGT TAATTGTGATAC	7617	7635
77	TGTGT TAATTGTGATACAT	7619	7637
78	TTAAAGTTACACT TGTGT T	8586	8604
79	TTACACT TGTGT TCCTTTT	8592	8610
80	ACACT TGTGT TCCTTTTGT	8594	8612
81	CACT TGTGT TCCTTTTGT	8595	8613
82	ACT TGTGT TCCTTTTGT	8596	8614
83	CT TGTGT TCCTTTTGTG	8597	8615
84	TGTGT TCCTTTTGTGCT	8598	8616
85	TGTGT TCCTTTTGTGCT	8599	8617
86	ACATCAGCT TGTGT TTTGG	8993	9011
87	ATCAGCT TGTGT TTTGGCT	8995	9013
88	CAGCT TGTGT TTTGGCTGC	8997	9015
89	AGCT TGTGT TTTGGCTGCT	8998	9016
90	GCT TGTGT TTTGGCTGCTG	8999	9017
91	CT TGTGT TTTGGCTGCTGA	9000	9018
92	TGTGT TTTGGCTGCTGAA	9001	9019
93	TGTGT TTTGGCTGCTGAAT	9002	9020
94	AGAAGCTGGTGT TGTGTA	9241	9259
95	AAGCTGGTGT TGTGT ATC	9243	9261
96	GCTGGTGT TGTGT ATCTA	9245	9263
97	TGGTGT TGTGT ATCTACT	9247	9265
98	GTGT TGTGT ATCTACTAG	9249	9267
99	GTT TGTGT ATCTACTAGTG	9251	9269
100	TT TGTGT ATCTACTAGTGG	9252	9270
101	TGTGT ATCTACTAGTGGT	9253	9271
102	TGTGT ATCTACTAGTGGTA	9254	9272
103	TAGATTATGACT TGTGT CTC	10509	10527
104	GATTATGACT TGTGT CTCTT	10511	10529

Supplemental Table 1

105	TTATGACT TGTGT CTCTTTTT	10513	10531
106	ATGACT TGTGT CTCTTTTTTG	10515	10533
107	TGACT TGTGT CTCTTTTTGT	10516	10534
108	GACT TGTGT CTCTTTTTGTT	10517	10535
109	ACT TGTGT CTCTTTTTGTTA	10518	10536
110	CTGTGT CTCTTTTTGTTAC	10519	10537
111	TGTGT CTCTTTTTGTTACA	10520	10538
112	TGCCGTTTTAGATA TGTGT	10831	10849
113	GCCGTTTTAGATA TGTGTG	10832	10850
114	CCGTTTTAGATA TGTGTGC	10833	10851
115	CGTTTTAGATA TGTGTGCT	10834	10852
116	GTTTTAGATA TGTGTGCTT	10835	10853
117	TTTTAGATA TGTGTGCTTC	10836	10854
118	TTAGATA TGTGTGCTTCAT	10838	10856
119	AGATA TGTGTGCTTCATTA	10840	10858
120	ACT TGTGT TATGTATGCATC	11307	11325
121	TGTGT TATGTATGCATCAG	11309	11327
122	AGA ACTGTGT ATGATGATG	11357	11375
123	AA CTGTGT ATGATGATGGT	11359	11377
124	ACT TGTGT ATGATGATGGTG	11360	11378
125	CTGTGT ATGATGATGGTGC	11361	11379
126	TGTGT ATGATGATGGTGCT	11362	11380
127	AGG TATTGTTTTTATGTGT	11533	11551
128	GG TATTGTTTTTATGTGTG	11534	11552
129	GT ATTGTTTTTATGTGTGT	11535	11553
130	T ATTGTTTTTATGTGTGTT	11536	11554
131	AT TGTTTTTATGTGTGTTG	11537	11555
132	TT GTTTTTATGTGTGTTGA	11538	11556
133	T GTTTTTATGTGTGTTGAG	11539	11557
134	G TTTTTATGTGTGTTGAGT	11540	11558
135	TT TTATGTGTGTTGAGTAT	11542	11560
136	TT TATGTGTGTTGAGTATT	11543	11561
137	TT ATGTGTGTTGAGTATTG	11544	11562
138	TA TGTGTGTTGAGTATTGC	11545	11563
139	TGTGTGTTGAGTATTGCC	11547	11565
140	TGTGTTGAGTATTGCCCTA	11549	11567
141	ATTGTGGGCTCA ATGTGTC	11923	11941
142	TTGTGGGCTCA ATGTGTCC	11924	11942
143	TGTGGGCTCA ATGTGTCCA	11925	11943
144	TGGGCTCA ATGTGTCCAGT	11927	11945
145	TGCAAGAGATGG TTGTGTT	12418	12436
146	AGATGG TTGTGTTCCCTTG	12424	12442
147	ATGG TTGTGTTCCCTTGAA	12426	12444
148	G TTGTGTTCCCTTGAACAT	12429	12447
149	CTA ATTGTGTTAAGATGTT	13140	13158
150	TA ATTGTGTTAAGATGTTG	13141	13159
151	AA TTGTGTTAAGATGTTGT	13142	13160
152	AT TTGTGTTAAGATGTTGTG	13143	13161
153	TTGTGTTAAGATGTTGTGT	13144	13162
154	TGTGTTAAGATGTTGTGTA	13145	13163
155	GTG TTAAGATGTTGTGTAC	13146	13163
156	AA TTGTGTTAACTGTTTGG	14329	14347
157	AT TTGTGTTAACTGTTTGG	14330	14348

Supplemental Table 1

158	<u>TTGTGT</u> TAACTGTTTGGAT	14331	14349
159	<u>TGTGT</u> TAACTGTTTGGATG	14332	14350
160	TTTAAGGAATTACT <u>TGTGT</u>	14542	14560
161	GGAATTACT <u>TGTGT</u> ATGCT	14547	14565
162	AATTACT <u>TGTGT</u> ATGCTGC	14549	14567
163	TACT <u>TGTGT</u> ATGCTGCTG	14551	14569
164	ACT <u>TGTGT</u> ATGCTGCTGAC	14553	14571
165	TTCTATGACTTTGCT <u>TGTGT</u>	14695	14713
166	CTATGACTTTGCT <u>TGTGT</u> CT	14697	14715
167	TGACTTTGCT <u>TGTGT</u> CTAAG	14700	14718
168	ACTTTGCT <u>TGTGT</u> CTAAGGG	14702	14720
169	TTTGCT <u>TGTGT</u> CTAAGGGTT	14704	14722
170	TTGCT <u>TGTGT</u> CTAAGGGTTT	14705	14723
171	TGCT <u>TGTGT</u> CTAAGGGTTTC	14706	14724
172	GCT <u>TGTGT</u> CTAAGGGTTTCT	14707	14725
173	C <u>TGTGT</u> CTAAGGGTTTCTT	14708	14726
174	<u>TGTGT</u> CTAAGGGTTTCTTT	14709	14727
175	GTGAAATGGTCAT <u>TGTGT</u> GG	15431	15449
176	AAATGGTCAT <u>TGTGT</u> GGCGG	15434	15452
177	ATGGTCAT <u>TGTGT</u> GGCGGTT	15436	15454
178	GGTCAT <u>TGTGT</u> GGCGGTTCA	15438	15456
179	TCTGACGATGCTGT <u>TGTGT</u>	15715	15733
180	CTGACGATGCTGT <u>TGTGT</u> G	15716	15734
181	TGACGATGCTGT <u>TGTGT</u> G	15717	15735
182	GACGATGCTGT <u>TGTGT</u> GTT	15718	15736
183	ACGATGCTGT <u>TGTGT</u> GTTT	15719	15737
184	CGATGCTGT <u>TGTGT</u> GTTTC	15720	15738
185	ATGCTGT <u>TGTGT</u> GTTTCAA	15722	15740
186	GCTGT <u>TGTGT</u> GTTTCAATA	15724	15742
187	TGT <u>TGTGT</u> GTTTCAATAGC	15726	15744
188	G <u>TGTGT</u> TTCATAGCACTT	15730	15748
189	CAGGGTGATGATTAT <u>TGTGT</u>	15904	15922
190	AGGGTGATGATTAT <u>TGTGT</u> A	15905	15923
191	GGGTGATGATTAT <u>TGTGT</u> AC	15906	15924
192	GGTGATGATTAT <u>TGTGT</u> ACC	15907	15925
193	TGATGATTAT <u>TGTGT</u> ACCTT	15909	15927
194	GATTAT <u>TGTGT</u> ACCTTCCTT	15913	15931
195	AGGCTGTTGGGGCT <u>TGTGT</u>	16235	16253
196	GGCTGTTGGGGCT <u>TGTGT</u> T	16236	16254
197	GCTGTTGGGGCT <u>TGTGT</u> TTC	16237	16255
198	CTGTTGGGGCT <u>TGTGT</u> TCT	16238	16256
199	TGTTGGGGCT <u>TGTGT</u> TCTT	16239	16257
200	GTTGGGGCT <u>TGTGT</u> TCTTT	16240	16258
201	TTGGGGCT <u>TGTGT</u> TCTTTG	16241	16259
202	TGGGGCT <u>TGTGT</u> TCTTTGC	16242	16260
203	GGGCT <u>TGTGT</u> TCTTTGCAA	16244	16262
204	GGCT <u>TGTGT</u> TCTTTGCAAT	16245	16263
205	GCT <u>TGTGT</u> TCTTTGCAATT	16246	16264
206	CT <u>TGTGT</u> TCTTTGCAATTC	16247	16265
207	CATTAGTTTTCCATT <u>TGTGT</u>	16470	16488
208	ATTAGTTTTCCATT <u>TGTGT</u> G	16471	16489
209	TTAGTTTTCCATT <u>TGTGT</u> GC	16472	16490
210	TAGTTTTCCATT <u>TGTGT</u> GCT	16473	16491

Supplemental Table 1

211	GTTTTCCATT TGTGT GCTAA	16475	16493
212	TTTCCATT TGTGT GCTAATG	16477	16495
213	TCCATT TGTGT GCTAATGGA	16479	16497
214	TGTGT TGGTAGCGATAATG	16525	16543
215	TTTCAATTCAG TGTGT AGA	17499	17517
216	TTCAG TGTGT AGACTTATG	17505	17523
217	CTGAAGGTTTAT TGTGT TGA	18143	18161
218	GAAGGTTTAT TGTGT TGACA	18145	18163
219	AGGTTTAT TGTGT TGACATA	18147	18165
220	TAT TGTGT TGACATACCTGG	18152	18170
221	AGGTTTCATCTAAG TGTGTG	20475	20493
222	GGTTCATCTAAG TGTGTGT	20476	20494
223	GTTTCATCTAAG TGTGTGTG	20477	20495
224	TCATCTAAG TGTGTGTGT T	20479	20497
225	ATCTAAG TGTGTGTGT TCT	20481	20499
226	CTAAG TGTGTGTGT TCTGT	20483	20501
227	AAG TGTGTGTGT TCTGTTA	20485	20503
228	AG TGTGTGTGT TCTGTATT	20486	20504
229	TGTGTGTG TCTGTATT	20487	20505
230	TGTGTGT TCTGTATTG	20488	20506
231	TGTGTGT TCTGTATTGA	20489	20507
232	TGTGTGT TCTGTATTGAT	20490	20508
233	TGTGT TCTGTATTGATT	20491	20509
234	TGTGT TCTGTATTGATTT	20492	20510
235	AGTCTCTAGTCAG TGTGT T	21592	21610
236	TCTCTAGTCAG TGTGT TAA	21594	21612
237	TCTAGTCAG TGTGT TAATC	21596	21614
238	TAGTCAG TGTGT TAATCTT	21598	21616
239	ATCTTAGGGAATTT TGTGT T	22125	22143
240	TCTTAGGGAATTT TGTGT TT	22126	22144
241	CTTAGGGAATTT TGTGT TTA	22127	22145
242	TAGGGAATTT TGTGT TTAAG	22129	22147
243	GGGAATTT TGTGT TTAAGAA	22131	22149
244	ATTT TGTGT TTAAGAATATT	22135	22153
245	TT TGTGT TTAAGAATATTG	22136	22154
246	TT TGTGT TTAAGAATATTGA	22137	22155
247	TGTGT TTAAGAATATTGAT	22138	22156
248	CTGTGT TGCTGATTATTCT	22642	22660
249	TGTGT TGCTGATTATTCTG	22643	22661
250	ATGTCAGAG TGTGT ACTTG	24647	24665
251	GTCAGAG TGTGT ACTTGGA	24649	24667
252	ACATTT TGTGT CTGGTAACT	24920	24938
253	ATTT TGTGT CTGGTAACTGT	24922	24940
254	TT TGTGT CTGGTAACTGTG	24923	24941
255	TT TGTGT CTGGTAACTGTGA	24924	24942
256	TGTGT CTGGTAACTGTGAT	24925	24943
257	TGGAGTAAAAGACT TGTGT T	25977	25995
258	GAGTAAAAGACT TGTGT TGT	25979	25997
259	GAAAAGACT TGTGT TGTAT	25981	25999
260	TGTGT TGTATTACACAGTT	25990	26008
261	ACTGCGCTTCGATT TGTGTG	26347	26365
262	CTGCGCTTCGATT TGTGTG C	26348	26366
263	TGCGCTTCGATT TGTGTG CG	26349	26367

Supplemental Table 1

264	CGCTTCGATT TGTGT GCGTA	26351	26369
265	CTTCGATT TGTGT GCGTACT	26353	26371
266	TCGATT TGTGT GCGTACTGC	26355	26373
267	GATT TGTGT GCGTACTGCTG	26357	26375
268	TGTGT GCGTACTGCTGCA	26359	26377
269	CCAAGAG TGTGT TAGAGGT	27453	27471
270	AG TGTGT AACATTAGGGAG	29687	29705
271	GTGTGT AACATTAGGGAGG	29688	29706

Supplemental Table 1**List of SARS-CoV-2 GU-rich sequences enriched in Interferon Induction Motif (IIM)**

The reference SARS-CoV-2 genome (NC_045512, positive strand) was scanned for GU-rich ssRNA as explained in Material and Methods. Within the identified 491 GU-rich sequences, 271 were further selected based on their content of at least one "UGUGU" Interferon Induction Motif (IIM). Base numbering is based on the SARS-CoV-2 reference genome NC_045512.

Gene Name	Species	Primer Sequence (5'-3')	
RPL32	mouse	Forward Reverse	GCTGCCATCTGTTTTACGG TGACTGGTGCCTGATGAACT
TLR1	mouse	Forward Reverse	CTGTCTTCAGATGCTTACCTCC GGATGCTACATTGAGTTCCTGC
TLR2	mouse	Forward Reverse	CAGCTCACCGATGAAGAAGCTG GAACTCTACCTCCGACAGTTCC
TLR3	mouse	Forward Reverse	CGAACCTGACAGAACTCGATC TTGGAGGTTCTCCAGTTGGAC
TLR4	mouse	Forward Reverse	CACGTCCATCGGTTGATCTTGG AGTCCTTCCATGATAGAGGGTTC
TLR5	mouse	Forward Reverse	TGCTAACAAAGCTGACCGTGCTC TTCACAGTTGCAGACGAACTCG
TLR6	mouse	Forward Reverse	GAGCTGAGAGTTCTGAGACTC CCGATTGTGTGAGACATCCAG
TLR7	mouse	Forward Reverse	TGATCCTGGCCTATCTCTGAC CGTGTCCACATCGAAAACAC
TLR8	mouse	Forward Reverse	TGGCATTACACCCTCACAGAG CATTCCACAAACGGTCAAGACG
TLR9	mouse	Forward Reverse	CATCACCTGAGCCATCTGGAAG GAGGTTGACCAGACCTTGGAACT
TLR11	mouse	Forward Reverse	TCTCACCAGTTTCATTCTGCTGC GAGTGTCCAGAGGTGATGAAGC
TNF-α	mouse	Forward Reverse	TGCCTATGTCTCAGCCTCTTC GAGGCCATTTGGGAACTTCT
IL-1β	mouse	Forward Reverse	TGTAATGAAAGACGGCACACC TCTTCTTTGGGTATTGCTTGG
IL-6	mouse	Forward Reverse	GCTACCAAAGTGGATATAATCAGGA CCAGGTAGCTATGGTACTCCAGAA
IFN-α4	mouse	Forward Reverse	TCAAGCCATCCTTGTGCTAA GTCTTTTGTGTAAGAGGTT
IFN-γ	mouse	Forward Reverse	ATCTGGAGGAACTGGCAAAA TTCAAGACTTCAAAGAGTCTGAGGTA
CCL3	mouse	Forward Reverse	TGCCTGCTGCTTCTCCTACAGC CCCAGGTCTCTTTGGAGTCAGC
CCL4	mouse	Forward Reverse	TGTGCTCCAGGGTTCTCAGCAC GGTTAGCACAGATCTGTCTGC
CCL20	mouse	Forward Reverse	AACTGGGTGAAAAGGGCTGT GTCCAATTCCATCCCAAAA
CCL22	mouse	Forward Reverse	TCTTGCTGTGGCAATTCAGA GAGGGTGACGGATGTAGTCC
CXCL10	mouse	Forward Reverse	CGTCATTTTCTGCCTCATCCTG CCGTCATCGATATGGATGCAGT
TRAIL	mouse	Forward Reverse	CTCACATTACTGGGATCACTCG CTCCCAGGATTCAATCTTCTGG
Granzyme B	mouse	Forward Reverse	CCCAAAGACCAAACGTGCTTCC AAGCACGTGGAGGTGAACCATC
HPRT	human	Forward Reverse	CCAGTCAACAGGGGACATAAA CACAATCAAGACATTCTTCCAGT

<i>TLR7</i>	human	Forward Reverse	TTAACCAATTGCTTCCGTGTC GGTGCCACACTCAATCTG
<i>TLR8</i>	human	Forward Reverse	TGTGGTTGTTTTCTGGATTCAA GCTCGCATGGCTTACATGA

Supplemental Table 2. Primer list used for qPCR.